Fig. 6. Regulating PKM2 activity alleviates cisplatin-induced AKI in vivo.

A Western blots result of PKM2, MYH9, and DRP1 expression in mitochondria isolated from mice after cisplatin injection at day 1 pretreated with or without Shikonin. B Western blot results of PKM2, MYH9, and DRP1 expression in mitochondria isolated from mice after cisplatin injection at day 1 pretreated with or without TEPP46. C, D Representative images of TEM and quantification of mean mitochondrial area (μm²) in proximal tubular epithelial cells from cisplatin injected mice pretreated Shikonin or TEPP46. scale bar = 500 nm. *P < 0.05, n = 6–8 per group. E, F The BUN level or urinary KIM-1 to creatinine ratio of mice 3 days after cisplatin injury pretreated with Shikonin or TEPP46. *P <0.05, n = 6–8 per group. G, H Representative images of H&E and PAS staining of kidney tissues from cisplatin injected mice pretreated with Shikonin or TEPP46. scale bar=50 μm. I Western blot analysis of Na/K-ATPase, AQP1, KIM-1, cleaved-caspase3, caspase3, RIP1, p-RIP3, RIP3, p-MLKL, MLKL, and GPX4 expression in kidney tissues from cisplatin injected mice pretreated with or without Shikonin. J Western blot analysis of Na/K-ATPase, AQP1, KIM-1, cleaved-caspase3, caspase3, RIP1, p-RIP3, RIP3, p-MLKL, MLKL, and GPX4 expression in kidney tissues from cisplatin injected mice pretreated with or without TEPP46. K, L Representative images of immunohistochemical and immunofluorescent staining for KIM-1, TUNEL in kidney tissues from cisplatin injected mice pretreated with Shikonin or TEPP46. scale bar = 50 μm. M Quantitative analysis of TUNEL positive cells among groups as indicated. scale bar = 50 μm. *P < 0.05, n = 6–8 per group.